Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Cardiovascular Translational Research
Published in: Journal of Cardiovascular Translational Research 2/2016

01-04-2016 | Review

Endothelial Repair and Regeneration Following Intimal Injury

Author: Belay Tesfamariam

Published in: Journal of Cardiovascular Translational Research | Issue 2/2016

Login to get access

Abstract

Coronary artery intervention using device implants significantly reduce the risk of restenosis and the need for revascularization but are associated with endothelial denudation and impaired function. This may be due to incomplete endothelial recovery as a result of intimal injury, presence of polymer and/or high antiproliferative drug accumulation in the intima. The permanent presence of a metal prosthesis or polymer may impair the proliferation of resident endothelial cells to cover empty areas. Attention has focused on the robust replenishment of endothelial monolayer by recruitment of circulating endothelial progenitor cells derived from the bone marrow to areas of endothelial injury. The balance between endothelial damage and repair is critical for the maintenance of intimal integrity, function, and prevention of thrombotic complications. This review will discuss on the aftereffects of intravascular device implants on endothelial injury and the pathways involved in endothelial repair and regeneration with an emphasis on endothelial progenitor cells.
Literature
1.
Massberg, S., Schulz, C., & Gawaz, M. (2003). Role of platelets in the pathophysiology of acute coronary syndrome. Seminars in Vascular Medicine, 3(2), 147–162.CrossRefPubMed
2.
Jackson, S. P., Nesbitt, W. S., & Kulkarni, S. (2003). Signaling events underlying thrombus formation. Journal of Thrombosis and Haemostasis, 1(7), 1602–1612.CrossRefPubMed
3.
Konstantinides, S., Schäfer, K., Thinnes, T., & Loskutoff, D. J. (2001). Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice. Circulation, 103(4), 576–583.CrossRefPubMed
4.
Koppara, T., Cheng, Q., Yahagi, K., Mori, H., Sanchez, O. D., Feygin, J., et al. (2015). Thrombogenicity and early vascular healing response in metallic biodegradable polymer-based and fully bioabsorbable drug-eluting stents. Circulation. Cardiovascular Interventions, 8(6), e002427.CrossRefPubMed
5.
Tesfamariam, B. (2008). Platelet function in intravascular device implant-induced intimal injury. Cardiovascular Revascularization Medicine, 9(2), 78–87.CrossRefPubMed
6.
Otsuka, F., Finn, A. V., Yazdani, S. K., Nakano, M., Kolodgie, F. D., & Virmani, R. (2012). The importance of the endothelium in atherothrombosis and coronary stenting. Nature Reviews Cardiology, 9(8), 439–453.CrossRefPubMed
7.
8.
Muldowney, J. A., 3rd, Stringham, J. R., Levy, S. E., Gleaves, L. A., Eren, M., Piana, R. N., et al. (2007). Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents. Arteriosclerosis, Thrombosis, and Vascular Biology, 27(2), 400–406.CrossRefPubMed
9.
Ara, J., Mirapeix, E., Arrizabalaga, P., Rodriguez, R., Ascaso, C., Abellana, R., et al. (2001). Circulating soluble adhesion molecules in ANCA-associated vasculitis. Nephrology, Dialysis, Transplantation, 16, 276–285.CrossRefPubMed
10.
Cai, H. (2005). NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and vascular disease. Circulation Research, 96(8), 818–822.CrossRefPubMed
11.
Blum, A., Schneider, D. J., Sobel, B. E., & Dauerman, H. L. (2004). Endothelial dysfunction and inflammation after percutaneous coronary intervention. American Journal of Cardiology, 94(11), 1420–1423.CrossRefPubMed
12.
Hofma, S. H., van der Giessen, W. J., van Dalen, B. M., Lemos, P. A., McFadden, E. P., Sianos, G., et al. (2006). Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. European Heart Journal, 27(2), 166–170.CrossRefPubMed
13.
Togni, M., Windecker, S., Cocchia, R., Wenaweser, P., Cook, S., Billinger, M., et al. (2005). Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. Journal of the American College of Cardiology, 46(2), 231–236.CrossRefPubMed
14.
Pendyala, L. K., Li, J., Shinke, T., Geva, S., Yin, X., Chen, J. P., et al. (2009). Endothelium-dependent vasomotor dysfunction in pig coronary arteries with paclitaxel-eluting stents is associated with inflammation and oxidative stress. JACC Cardiovascular Interventions, 2(3), 253–262.CrossRefPubMed
15.
Tesfamariam, B. (2008). Drug release kinetics from stent device-based delivery systems. Journal of Cardiovascular Pharmacology, 51(2), 118–125.CrossRefPubMed
16.
Stähli, B. E., Camici, G. G., Steffel, J., Akhmedov, A., Shojaati, K., Graber, M., et al. (2006). Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. Circulation Research, 99(2), 149–155.CrossRefPubMed
17.
Holy, E. W., Jakob, P., Eickner, T., Camici, G. G., Beer, J. H., Akhmedov, A., et al. (2014). PI3K/p110α inhibition selectively interferes with arterial thrombosis and neointima formation, but not re-endothelialization: potential implications for drug-eluting stent design. European Heart Journal, 35(12), 808–820.CrossRefPubMed
18.
Ma, Q., Zhou, Y., Nie, X., Yu, M., Gao, F., Wang, Z., et al. (2012). Rapamycin affects tissue plasminogen activator and plasminogen activator inhibitor I expression: a potential prothrombotic mechanism of drug-eluting stents. Angiology, 63(5), 330–335.CrossRefPubMed
19.
Togni, M., Räber, L., Cocchia, R., Wenaweser, P., Cook, S., Windecker, S., et al. (2007). Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. International Journal of Cardiology, 120(2), 212–220.CrossRefPubMed
20.
Jabs, A., Göbel, S., Wenzel, P., Kleschyov, A. L., Hortmann, M., Oelze, M., et al. (2008). Sirolimus-induced vascular dysfunction: increased mitochondrial and nicotinamide adenosine dinucleotide phosphate oxidase-dependent superoxide production and decreased vascular nitric oxide formation. Journal of the American College of Cardiology, 51(22), 2130–2138.CrossRefPubMed
21.
Camici, G. G., Steffel, J., Amanovic, I., Breitenstein, A., Baldinger, J., Keller, S., et al. (2010). Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents. European Heart Journal, 31(2), 236–242.CrossRefPubMed
22.
Liu, H. T., Li, F., Wang, W. Y., Li, X. J., Liu, Y. M., Wang, R. A., et al. (2010). Rapamycin inhibits re-endothelialization after percutaneous coronary intervention by impeding the proliferation and migration of endothelial cells and inducing apoptosis of endothelial progenitor cells. Texas Heart Institute Journal, 37(2), 194–201.PubMedPubMedCentral
23.
Potnis, P. A., Tesfamariam, B., & Wood, S. C. (2011). Induction of nicotinamide-adenine dinucleotide phosphate oxidase and apoptosis by biodegradable polymers in macrophages: implications for stents. Journal of Cardiovascular Pharmacology, 57(6), 712–720.CrossRefPubMed
24.
Nakano, M., Yahagi, K., Otsuka, F., Sakakura, K., Finn, A. V., Kutys, R., et al. (2014). Causes of early stent thrombosis in patients presenting with acute coronary syndrome: an ex vivo human autopsy study. Journal of the American College of Cardiology, 63, 2510–2520.CrossRefPubMed
25.
Wang, X., Zachman, A. L., Chun, Y. W., Shen, F. W., Hwang, Y. S., & Sung, H. J. (2014). Polymeric stent materials dysregulate macrophage and endothelial cell functions: implications for coronary artery stent. International Journal of Cardiology, 174(3), 688–695.CrossRefPubMedPubMedCentral
26.
Nührenberg, T. G., Voisard, R., Fahlisch, F., Rudelius, M., Braun, J., Gschwend, J., et al. (2005). Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplasty. FASEB Journal, 19(2), 246–248.PubMed
27.
van Beusekom, H. M., Sorop, O., van den Heuvel, M., Onuma, Y., Duncker, D. J., Danser, A. H., et al. (2010). Endothelial function rather than endothelial restoration is altered in paclitaxel- as compared to bare metal-, sirolimus and tacrolimus-eluting stents. EuroIntervention, 6(1), 117–125.CrossRefPubMed
28.
Nakazawa, G., Nakano, M., Otsuka, F., Wilcox, J. N., Melder, R., Pruitt, S., et al. (2011). Evaluation of polymer-based comparator drug-eluting stents using a rabbit model of iliac artery atherosclerosis. Circulation. Cardiovascular Interventions, 4(1), 38–46.CrossRefPubMed
29.
Otsuka, F., Byrne, R. A., Yahagi, K., Mori, H., Ladich, E., Fowler, D. R., et al. (2015). Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. European Heart Journal, 36(32), 2147–2159.CrossRefPubMed
30.
Joner, M., Nakazawa, G., Finn, A. V., Quee, S. C., Coleman, L., Acampado, E., et al. (2008). Endothelial cell recovery between comparator polymer-based drug-eluting stents. Journal of the American College of Cardiology, 52(5), 333–342.CrossRefPubMed
31.
32.
Torisu, T., Torisu, K., Lee, I. H., Liu, J., Malide, D., Combs, C. A., et al. (2013). Autophagy regulates endothelial cell processing, maturation and secretion of von Willebrand factor. Nature Medicine, 19(10), 1281–1287.CrossRefPubMedPubMedCentral
33.
34.
Hayashi, S., Yamamoto, A., You, F., Yamashita, K., Ikegame, Y., Tawada, M., et al. (2009). The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. American Journal of Pathology, 175(5), 2226–2234.CrossRefPubMedPubMedCentral
35.
Barilli, A., Visigalli, R., Sala, R., Gazzola, G. C., Parolari, A., Tremoli, E., et al. (2008). In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function. Cardiovascular Research, 78, 563–571.CrossRefPubMed
36.
Guo, F., Li, X., Peng, J., Tang, Y., Yang, Q., Liu, L., et al. (2014). Autophagy regulates vascular endothelial cell eNOS and ET-1 expression induced by laminar shear stress in an ex vivo perfused system. Annals of Biomedical Engineering, 42(9), 1978–1988.CrossRefPubMed
37.
Perry, T. E., Song, M., Despres, D. J., Kim, S. M., San, H., Yu, Z. X., et al. (2009). Bone marrow-derived cells do not repair endothelium in a mouse model of chronic endothelial cell dysfunction. Cardiovascular Research, 84, 317–325.CrossRefPubMedPubMedCentral
38.
Blann, A. D., Woywodt, A., Bertolini, F., Bull, T. M., Buyon, J. P., Clancy, R. M., et al. (2005). Circulating endothelial cells. Biomarker of vascular disease. Thrombosis and Haemostasis, 93(2), 228–235.PubMed
39.
Quilici, J., Banzet, N., Paule, P., Meynard, J. B., Mutin, M., Bonnet, J. L., et al. (2004). Circulating endothelial cell count as a diagnostic marker for non-ST-elevation acute coronary syndromes. Circulation, 110(12), 1586–1591.CrossRefPubMed
40.
41.
Szmitko, P. E., Fedak, P. W., Weisel, R. D., Stewart, D. J., Kutryk, M. J., & Verma, S. (2003). Endothelial progenitor cells: New hope for a broken heart. Circulation, 107(24), 3093–3100.CrossRefPubMed
42.
Bonello, L., Harhouri, K., Baumstarck, K., Arnaud, L., Lesavre, N., Piot, C., et al. (2012). Mobilization of CD34+ KDR+ endothelial progenitor cells predicts target lesion revascularization. Journal of Thrombosis and Haemostasis, 10(9), 1906–1913.CrossRefPubMed
43.
Shantsila, E., Watson, T., & Lip, G. Y. (2007). Endothelial progenitor cells in cardiovascular disorders. Journal of the American College of Cardiology, 49(7), 741–752.CrossRefPubMed
44.
Ben Shoshan, J., & George, J. (2007). Endothelial progenitor cells as therapeutic vectors in cardiovascular disorders: from experimental models to human trials. Pharmacology and Therapeutics, 115(1), 25–36.CrossRefPubMed
45.
Rafii, S., & Lyden, D. (2003). Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nature Medicine, 9(6), 702–712.CrossRefPubMed
46.
Werner, N., Kosiol, S., Schiegl, T., Ahlers, P., Walenta, K., Link, A., et al. (2005). Circulating endothelial progenitor cells and cardiovascular outcomes. New England Journal of Medicine, 353(10), 999–1007.CrossRefPubMed
47.
Hill, J. M., Zalos, G., Halcox, J. P., Schenke, W. H., Waclawiw, M. A., Quyyumi, A. A., et al. (2003). Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. New England Journal of Medicine, 348(7), 593–600.CrossRefPubMed
48.
Urbich, C., & Dimmeler, S. (2004). Endothelial progenitor cells: characterization and role in vascular biology. Circulation Research, 95(4), 343–353.CrossRefPubMed
49.
Sata, M., Saiura, A., Kunisato, A., Tojo, A., Okada, S., Tokuhisa, T., et al. (2002). Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nature Medicine, 8(4), 403–409.CrossRefPubMed
50.
Larsen, K., Cheng, C., Tempel, D., Parker, S., Yazdani, S., den Dekker, W. K., et al. (2012). Capture of circulatory endothelial progenitor cells and accelerated re-endothelialization of a bio-engineered stent in human ex vivo shunt and rabbit denudation model. European Heart Journal, 33(1), 120–128.CrossRefPubMedPubMedCentral
51.
Takabatake, S., Hayashi, K., Nakanishi, C., Hao, H., Sakata, K., Kawashiri, M. A., et al. (2014). Vascular endothelial growth factor bound stents: application of in situ capture technology of circulating endothelial progenitor cells in porcine coronary model. Journal of Interventional Cardiology, 27(1), 63–72.CrossRefPubMed
52.
Pernagallo, S., Tura, O., Wu, M., Samuel, K., Diaz-Mochon, J. J., Hansen, A., et al. (2012). Novel biopolymers to enhance endothelialization of intra-vascular devices. Adv Healthc Mater, 1(5), 646–656.CrossRefPubMed
53.
Blindt, R., Vogt, F., Astafieva, I., Fach, C., Hristov, M., Krott, N., et al. (2006). A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells. Journal of the American College of Cardiology, 47(9), 1786–1795.CrossRefPubMed
54.
Heissig, B., Hattori, K., Dias, S., Friedrich, M., Ferris, B., Hackett, N. R., et al. (2002). Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell, 109(5), 625–637.CrossRefPubMedPubMedCentral
55.
Paradisi, G., Bracaglia, M., Basile, F., Di'Ipolito, S., Di Nicuolo, F., Ianniello, F., et al. (2012). Effect of pravastatin on endothelial function and endothelial progenitor cells in healthy postmenopausal women. Clinical and Experimental Obstetrics and Gynecology, 39(2), 153–159.PubMed
56.
Baran, Ç., Durdu, S., Dalva, K., Zaim, Ç., Dogan, A., Ocakoglu, G., et al. (2012). Effects of preoperative short term use of atorvastatin on endothelial progenitor cells after coronary surgery: a randomized, controlled trial. Stem Cell Reviews, 8(3), 963–971.CrossRefPubMed
57.
Walter, D. H., Zeiher, A. M., & Dimmeler, S. (2004). Effects of statins on endothelium and their contribution to neovascularization by mobilization of endothelial progenitor cells. Coronary Artery Disease, 15(5), 235–242.CrossRefPubMed
58.
Sugiura, T., Kondo, T., Kureishi-Bando, Y., Numaguchi, Y., Yoshida, O., Dohi, Y., et al. (2008). Nifedipine improves endothelial function: role of endothelial progenitor cells. Hypertension, 52(3), 491–498.CrossRefPubMed
59.
de Ciuceis, C., Pilu, A., Rizzoni, D., Porteri, E., Muiesan, M. L., Salvetti, M., et al. (2011). Effect of antihypertensive treatment on circulating endothelial progenitor cells in patients with mild essential hypertension. Blood Pressure, 20(2), 77–83.CrossRefPubMed
60.
Yao, E. H., Fukuda, N., Matsumoto, T., Katakawa, M., Yamamoto, C., Han, Y., et al. (2008). Effects of the antioxidative blocker celiprolol on endothelial progenitor cells in hypertensive rats. American Journal of Hypertension, 21(9), 1062–1068.CrossRefPubMed
61.
Santulli, G., Wronska, A., Uryu, K., Diacovo, T. G., Gao, M., Marx, S. O., et al. (2014). A selective microRNA-based strategy inhibits restenosis while preserving endothelial function. Journal of Clinical Investigation, 124(9), 4102–4114.CrossRefPubMedPubMedCentral
62.
Szmitko, P. E., Wang, C. H., Weisel, R. D., de Almeida, J. R., Anderson, T. J., & Verma, S. (2003). New markers of inflammation and endothelial cell activation: part I. Circulation, 108(16), 1917–1923.CrossRefPubMed
63.
Kozuka, K., Kohriyama, T., Nomura, E., Ikeda, J., Kajikawa, H., & Nakamura, S. (2002). Endothelial markers and adhesion molecules in acute ischemic stroke-sequential change and differences in stroke subtype. Atherosclerosis, 161, 161–168.CrossRefPubMed
64.
Sabatier, F., Camoin-Jau, L., Anfosso, F., Sampol, J., & Dignat-George, F. (2009). Circulating endothelial cells, microparticles and progenitors: key players towards the definition of vascular competence. Journal of Cellular and Molecular Medicine, 13(3), 454–471.CrossRefPubMedPubMedCentral
65.
Kümpers, P., Hellpap, J., David, S., Horn, R., Leitolf, H., Haller, H., et al. (2009). Circulating angiopoietin-2 is a marker and potential mediator of endothelial cell detachment in ANCA-associated vasculitis with renal involvement. Nephrology, Dialysis, Transplantation, 24(6), 1845–1850.CrossRefPubMed
66.
Vowinkel, T., Wood, K. C., Stokes, K. Y., Russell, J., Krieglstein, C. F., & Granger, D. N. (2006). Differential expression and regulation of murine CD40 in regional vascular beds. American Journal of Physiology Heart and Circulatory Physiology, 290(2), H631–639.CrossRefPubMed
67.
Burger, D., & Touyz, R. M. (2012). Cellular biomarkers of endothelial health: microparticles, endothelial progenitor cells, and circulating endothelial cells. Journal of the American Society of Hypertension, 6(2), 85–99.CrossRefPubMed
Metadata
Title
Endothelial Repair and Regeneration Following Intimal Injury
Author
Belay Tesfamariam
Publication date
01-04-2016
Publisher
Springer US
Published in
Journal of Cardiovascular Translational Research / Issue 2/2016
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI
https://doi.org/10.1007/s12265-016-9677-1

Other articles of this Issue 2/2016

Journal of Cardiovascular Translational Research 2/2016 Go to the issue

Letter to the Editor

Limitations in Translating Animal Studies to Humans in Cardiovascular Disease

Original Article

Nucleotide Catabolism on the Surface of Aortic Valve Xenografts; Effects of Different Decellularization Strategies

Correspondence

A New NO-Releasing Nanoformulation for the Treatment of Pulmonary Arterial Hypertension

Original Article

Clinical Outcome of Patients with Aortic Stenosis and Coronary Artery Disease Not Treated According to Current Recommendations

Review

Calcific Aortic Valve Disease: Part 1—Molecular Pathogenetic Aspects, Hemodynamics, and Adaptive Feedbacks

Original Article

Evaluation of the Mayo Clinic Phenotype-Based Genotype Predictor Score in Patients with Clinically Diagnosed Hypertrophic Cardiomyopathy

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits